
PMCBD
Healthcare · Biotechnology · $14.3M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 12, 2021 | Time not confirmed | — | -0.49 | — |
| Dec 11, 2020 | Time not confirmed | — | -0.62 | — |
| Aug 13, 2020 | Time not confirmed | — | -0.79 | — |
| Mar 13, 2020 | Time not confirmed | — | -0.95 | — |
| Aug 13, 2019 | Time not confirmed | — | -1.41 | — |
| Mar 14, 2019 | Time not confirmed | — | -0.90 | — |
| Jul 20, 2018 | Time not confirmed | — | -1.74 | — |
| Jun 27, 2018 | Time not confirmed | — | -1.92 | — |
| Mar 19, 2018 | Time not confirmed | — | -3.12 | — |
PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic…